이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

LAmbre™ II 좌심이첨 폐쇄기 및 비판막성 심방세동 환자를 위한 폐쇄기 전달 시스템 (LAmbre2)

2026년 9월 15일 업데이트: Dr So Chak Yu kent, Prince of Wales Hospital, Shatin, Hong Kong

비판막성 심방세동 환자를 위한 LAmbre™ II 좌심이첨 폐쇄기 및 폐쇄기 전달 시스템에 대한 최초 인간 대상 (FIM) 연구

Worldwide, atrial fibrillation (AF) is the most common cardiac arrhythmia in adults. The prevalence of AF gradually increases with age; its prevalence is 0.5% ~ 0.8% among 45 ~ 59 year-olds, 1.8% ~ 5.9% among 60 ~ 69 year-olds, and 6.7% ~17.9% among > 79 year-olds. Thromboembolic complications are the leading cause of death and disability in patients with AF, with ischemic stroke being the most common complication. AF significantly increases the risk of stroke by 3- to 5-fold due to thrombosis caused by abnormal atrial beat. The overall risk of ischemic stroke in patients with AF is 20% ~ 30%, and strokes due to atrial fibrillation account for 20% of all strokes.

In the current 2023 ACC/AHA/ACCP/HRS Guideline, percutaneous LAAC has been classified as a Class 2a indication for stroke prevention in patients with AF, a moderate to high risk of stroke, and a contraindication to long-term oral anticoagulation due to a nonreversible cause. However, the implantation procedure does have adverse effects which include serious pericardial effusion, procedure-related ischemic stroke, and device embolization. Due to the anatomical diversity of the LAA, certain patients are not candidates for this device.

The LAmbre™ Left Atrial Appendage Closure System, manufactured by Lifetech Scientific (Shenzhen) Co.Ltd., is the first generation of LAmbre LAAO device which is CE-marked and is current approved in Hong Kong Hospital Authority for regular clinical use. It consists of a LAA Occluder and a Delivery System and is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage in patients who have nonvalvular atrial fibrillation.

This self-expanding LAA Occluder consists of an umbrella and a cover connected by a central waist. Although the first generation of LAmbre LAAO device is associated with high implantation success rate of 99.7% and a relatively low major procedure-related complication rate of 2.9%, to better match the challenging anatomy of the LAA and to further improve procedural safety, the first generation of LAmbre LAAO device has been upgraded.

The LAmbre™ II Left Atrial Appendage Occluder, designed to prevent thrombus embolization and reduce the risk of bleeding events in patients with non-valvular atrial fibrillation, is being evaluated in a prospective, single-center, single-arm First In Man (FIM) study. The study, conducted at the Prince of Wales Hospital, Chinese University of Hong Kong, aims to assess the preliminary safety and feasibility of the device and its Occluder Delivery System in 10 subjects who are at increased risk for stroke and systemic embolism, either due to their anticoagulation therapy eligibility or contraindications.

The enrollment period is expected to take approximately 6 months and subjects will have follow-up before discharge and at 30 days, 3M, 6M, 12M months post-operation. The total study duration is expected to be approximately 19 months.

연구 개요

상태

모집하지 않고 적극적으로

연구 유형

중재적

등록 (추정된)

10

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Shatin, 홍콩
        • The Chinese University of Hong Kong

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • The patient age ≥18 years;
  • The patient has documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation;
  • The patient has a CHA2DS2-VASc score of ≥ 2 in men and CHA2DS2-VASc score of ≥ 3 in women;
  • The patient is recommended for oral anticoagulation therapy, but there is an appropriate rationale for seeking a non-pharmacologic alternative to oral anticoagulation;
  • The patient is deemed suitable for LAA closure by the site investigator and a clinician not a part of the procedural team in the shared decision-making process, and this determination has been documented in the patient's medical record;
  • The patient is willing and able to comply with the required medication post-procedure and follow-up evaluations;
  • The patient (or his or her legally authorized representative) has been informed of the nature of the study, agrees to its provisions, and has been provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).

Exclusion Criteria:

  • 1. Pregnant or nursing patients and those who plan pregnancy during the study period. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to the index procedure;
  • Patients with atrial fibrillation that is defined by a single occurrence, or that is transient or reversible (e.g., secondary to CABG, an interventional procedure, pneumonia, or hyperthyroidism);
  • Patients who require long-term anticoagulation for a condition other than atrial fibrillation;
  • Bleeding diathesis or coagulopathy;
  • Patients with rheumatic mitral valve disease, known severe mitral stenosis requiring surgical or percutaneous valve replacement, or existing mechanical valve prosthesis;
  • Active infection with bacteremia;
  • Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin, any device material or component (nickel titanium, PET, polypropylene), and/or contrast sensitivity;
  • Prior atrial septal defect (ASD) or patient foramen ovale (PFO) surgical repair or implantation of closure device;
  • Left atrial appendage is obliterated and surgical ligated;
  • Underwent any cardiac or non-cardiac interventional or surgical procedure within 30 days prior to the procedure or planned to have the interventional or surgical procedure within 60 days after implant procedure (e.g., cardioversion, ablation, percutaneous coronary intervention, cataract surgery, etc.);
  • Recent (within 90 days prior to procedure) stroke, transient ischemic attack, or myocardial infarction;
  • New York Heart Association Class IV;
  • Patients with severe renal failure (estimated glomerular filtration rate<30 ml/min/1.73m2);
  • Known asymptomatic carotid artery disease with>70% diameter stenosis OR symptomatic carotid disease (>50% diameter stenosis with ipsilateral stroke or TIA). Subjects with prior carotid endarterectomy or carotid stent placement may be enrolled, provided that known diameter stenosis is <50%;
  • Life expectancy is less than 1 year;
  • Current participation in another investigational drug or device study.

Echocardiographic Exclusion Criteria:

  • Left atrial appendage anatomy cannot accommodate the LAmbre II LAA Occluder per manufacturer IFU;
  • LVEF <30%;
  • Intracardiac thrombus or dense spontaneous echo contrast, as visualized by TEE prior to implant;
  • Presence of a high-risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (excursion >15 mm or length >15 mm) or large shunt (early, within 3 beats and/or substantial passage of 20 bubbles);
  • Existing circumferential pericardial effusion >5 mm;
  • Moderate or severe mitral valve stenosis (mitral valve area <1.5 cm2);
  • Complex atheroma with mobile plaque of the descending aorta and/or aortic arch;
  • Presence of a cardiac tumor

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 간섭

The LAmbre™ II Left Atrial Appendage Occluder, designed to prevent thrombus embolization and reduce the risk of bleeding events in patients with non-valvular atrial fibrillation

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
LAA closure success rate
기간: 3 months post-procedure

complete LAA closure or peri-device residual leak ≤3 mm measured by TEE at 3 months post-procedure

3 months post-procedure
Procedural complication rate
기간: peri-procedure

Rate of complication rate peri-procedure

peri-procedure

2차 결과 측정

결과 측정
측정값 설명
기간
Rate of death
기간: Perioperative

Rate of death at discharge

Perioperative
Rate of stroke
기간: Perioperative

Rate of stroke at discharge

Perioperative
Rate of stroke
기간: At 30 days post-OP

Rate of stroke at 30 days post-OP

At 30 days post-OP
Rate of stroke
기간: At 6 months post-OP

Rate of stroke at 6 months post-OP

At 6 months post-OP
Rate of stroke
기간: At 12 months post-OP

Rate of stroke at 12 months post-OP

At 12 months post-OP
Rate of systemic embolism
기간: Perioperative

Rate of systemic embolism at discharge

Perioperative
Rate of systemic embolism
기간: At 30 days post-OP

Rate of systemic embolism at 30 days post-OP

At 30 days post-OP
Rate of systemic embolism
기간: At 3 months post-OP

Rate of systemic embolism at 3 months post-OP

At 3 months post-OP
Rate of systemic embolism
기간: At 6 months post-OP

Rate of systemic embolism at 6 months post-OP

At 6 months post-OP
Rate of systemic embolism
기간: At 12 months post-OP

Rate of systemic embolism at 12 months post-OP

At 12 months post-OP
Rate of pericardial effusion with tamponade
기간: Perioperative

Rate of pericardial effusion with tamponade at discharge

Perioperative
Rate of pericardial effusion with tamponade
기간: At 30 days post-OP

Rate of pericardial effusion with tamponade at 30 days post-OP

At 30 days post-OP
Rate of pericardial effusion with tamponade
기간: At 3 months post-OP

Rate of pericardial effusion with tamponade at 3 months post-OP

At 3 months post-OP
Rate of pericardial effusion with tamponade
기간: At 6 months post-OP

Rate of pericardial effusion with tamponade at 6 months post-OP

At 6 months post-OP
Rate of pericardial effusion with tamponade
기간: At 12 months post-OP

Rate of pericardial effusion with tamponade at 12 months post-OP

At 12 months post-OP
Rate of pericardial effusion requiring drainage
기간: Perioperative

Rate of pericardial effusion requiring drainage at discharge

Perioperative
Rate of pericardial effusion requiring drainage
기간: At 30 days post-OP

Rate of pericardial effusion requiring drainage at 30 days post-OP

At 30 days post-OP
Rate of pericardial effusion requiring drainage
기간: At 3 months post-OP

Rate of pericardial effusion requiring drainage at 3 months post-OP

At 3 months post-OP
Rate of pericardial effusion requiring drainage
기간: At 6 months post-OP

Rate of pericardial effusion requiring drainage at 6 months post-OP

At 6 months post-OP
Rate of pericardial effusion requiring drainage
기간: At 12 months post-OP

Rate of pericardial effusion requiring drainage at 12 months post-OP

At 12 months post-OP
Rate of device embolization
기간: Perioperative

Rate of device embolization at discharge

Perioperative
Rate of device embolization
기간: At 30 days post-OP

Rate of device embolization at discharge at 30 days post-OP

At 30 days post-OP
Rate of device embolization
기간: At 3 months post-OP

Rate of device embolization at 3 months post-OP

At 3 months post-OP
Rate of death
기간: At 30 days

Rate of death at 30 days

At 30 days
Rate of death
기간: At 3 months post-OP

Rate of death at 3 months post-OP

At 3 months post-OP
Rate of death
기간: At 6 months post-OP

Rate of death at 6 months post-OP

At 6 months post-OP
Rate of death
기간: At 12 months post-OP

Rate of death at 12 months post-OP

At 12 months post-OP
Rate of device embolization
기간: At 6 months post-OP

Rate of device embolization at 6 months post-OP

At 6 months post-OP
Rate of device embolization
기간: At 12 months post-OP

Rate of device embolization at 12 months post-OP

At 12 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
기간: Perioperative

Rate of major bleeding (BARC defined 3 to 5) at discharge

Perioperative
Rate of major bleeding (BARC defined 3 to 5)
기간: At 30 days post-OP

Rate of major bleeding (BARC defined 3 to 5) at 30 days post-OP

At 30 days post-OP
Rate of major bleeding (BARC defined 3 to 5)
기간: At 3 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 3 months post-OP

At 3 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
기간: At 6 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 6 months post-OP

At 6 months post-OP
Rate of major bleeding (BARC defined 3 to 5)
기간: At 12 months post-OP

Rate of major bleeding (BARC defined 3 to 5) at 12 months post-OP

At 12 months post-OP
Closure success assessed by TEE or cardiac computed tomography
기간: At 30 days post-procedure

Closure success assessed by TEE or cardiac computed tomography at 30 days post-procedure

At 30 days post-procedure
Closure success assessed by TEE or cardiac computed tomography
기간: At 6 months post-procedure

Closure success assessed by TEE or cardiac computed tomography at 6 months post-procedure

At 6 months post-procedure
Closure success assessed by TEE or cardiac computed tomography
기간: At 12 months post-procedure

Closure success assessed by TEE or cardiac computed tomography at 12 months post-procedure

At 12 months post-procedure
Rate of minor bleeding (BARC type 2)
기간: At discharge, 30 days and 3, 6, 12 months post-procedure

Rate of minor bleeding (BARC type 2) at discharge

At discharge, 30 days and 3, 6, 12 months post-procedure
Rate of minor bleeding (BARC type 2)
기간: At 30 days post-procedure

Rate of minor bleeding (BARC type 2) at 30 days post-procedure

At 30 days post-procedure
Rate of minor bleeding (BARC type 2)
기간: At 3 months post-procedure

Rate of minor bleeding (BARC type 2) at 3 months post-procedure

At 3 months post-procedure
Rate of minor bleeding (BARC type 2)
기간: At 6 months post-procedure

Rate of minor bleeding (BARC type 2) at 6 months post-procedure

At 6 months post-procedure
Rate of minor bleeding (BARC type 2)
기간: At 12 months post-procedure

Rate of minor bleeding (BARC type 2) at 12 months post-procedure

At 12 months post-procedure
Rate of cardiovascular death
기간: Perioperative

Rate of cardiovascular death at discharge

Perioperative
Rate of cardiovascular death
기간: At 30 days post-procedure

Rate of cardiovascular death at 30 days post-procedure.

At 30 days post-procedure
Rate of cardiovascular death
기간: At 3 months post-procedure

Rate of cardiovascular death at 3 months post-procedure.

At 3 months post-procedure
Rate of cardiovascular death
기간: At 6 months post-procedure

Rate of cardiovascular death at 6 months post-procedure.

At 6 months post-procedure
Rate of cardiovascular death
기간: At 12 months post-procedure

Rate of cardiovascular death at 12 months post-procedure.

At 12 months post-procedure
Rate of ischemic stroke
기간: Perioperative

Rate of ischemic stroke at discharge

Perioperative
Rate of ischemic stroke
기간: At 30 days post-procedure

Rate of ischemic stroke at 30 days post-procedure

At 30 days post-procedure
Rate of ischemic stroke
기간: At 3 months post-procedure

Rate of ischemic stroke at 3 months post-procedure

At 3 months post-procedure
Rate of ischemic stroke
기간: At 6 months post-procedure

Rate of ischemic stroke at 6 months post-procedure

At 6 months post-procedure
Rate of ischemic stroke
기간: At 12 months post-procedure

Rate of ischemic stroke at 12 months post-procedure

At 12 months post-procedure
Rate of hemorrhagic stroke
기간: Perioperative

Rate of hemorrhagic stroke at discharge

Perioperative
Rate of hemorrhagic stroke
기간: At 30 days post-procedure

Rate of hemorrhagic stroke at 30 days post-procedure

At 30 days post-procedure
Rate of hemorrhagic stroke
기간: At 3 months post-procedure

Rate of hemorrhagic stroke at 3 months post-procedure

At 3 months post-procedure
Rate of hemorrhagic stroke
기간: At 6 months post-procedure

Rate of hemorrhagic stroke at 6 months post-procedure

At 6 months post-procedure
Rate of hemorrhagic stroke
기간: At 12 months post-procedure

Rate of hemorrhagic stroke at 12 months post-procedure

At 12 months post-procedure
Rate of systemic embolization
기간: Perioperative

Rate of systemic embolization at discharge

Perioperative
Rate of systemic embolization
기간: At 30 days post-procedure

Rate of systemic embolization at 30 days post-procedure

At 30 days post-procedure
Rate of systemic embolization
기간: At 3 months post-procedure

Rate of systemic embolization at 3 months post-procedure

At 3 months post-procedure
Rate of systemic embolization
기간: At 6 months post-procedure

Rate of systemic embolization at 6 months post-procedure

At 6 months post-procedure
Rate of systemic embolization
기간: At 12 months post-procedure

Rate of systemic embolization at 12 months post-procedure

At 12 months post-procedure
Procedural Technical success rate
기간: During procedure

Procedural Technical success rate, defined as successful delivery and release of study device with acceptable device position and stability, and closure success;

During procedure
Procedural success rate
기간: Peri-procedure

Procedural success rate, defined as technical success without major peri-procedural complications

Peri-procedure
Rate of Device-related thrombosis
기간: At 30 days post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 30 days post-procedure

At 30 days post-procedure
Rate of Device-related thrombosis
기간: At 3 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 3 months post-procedure

At 3 months post-procedure
Rate of Device-related thrombosis
기간: At 6 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 6 months post-procedure

At 6 months post-procedure
Rate of Device-related thrombosis
기간: At 12 months post-procedure

Rate of Device-related thrombosis, defined as the detection of thrombus adherent to the left atrial side of the device by TEE or cardiac computed tomography at 12 months post-procedure

At 12 months post-procedure

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 5일

기본 완료 (추정된)

2027년 11월 1일

연구 완료 (추정된)

2028년 5월 1일

연구 등록 날짜

최초 제출

2026년 2월 25일

QC 기준을 충족하는 최초 제출

2026년 3월 2일

처음 게시됨 (실제)

2026년 3월 6일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 15일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다